diabetes

Problems for GlaxoSmithKline just seem to be getting worse. The European Medicines Agency said Friday it's launching a new review of Avandia's benefit-risk profile following new data on the possibility of cardiovascular complications.

GlaxoSmithKline's diabetes drug Avandia once again captured headlines Monday morning after two new studies linked it to heart attacks and other cardiovascular complications. The authors of the studies say the results should prompt the FDA to pull the drug from the market.

Pharmaceutical giant Roche said Friday that it would delay an FDA filing for its new diabetes drug for 12 to 18 months due to safety concerns. The beneficiary of Roche's misfortune is rival Amylin, which now jumps ahead in the race to get first approval of a once-weekly injectable type 2 diabetes drug.

The financial media's coverage of China tends to focus on trade-related topics, but China is undergoing deep cultural shifts that will significantly alter its economic landscape. These four long-term trends could drastically change China -- and its relationship with the world.

Resveratrol, a substance found in red wine, could slow age-related disease and extend patients' life spans. But GlaxoSmithKline has suspended a trial of a resveratrol drug as a result of safety concerns.

One of the world's largest drug companies, AstraZeneca, agreed to pay $520 million to settle a U.S. government lawsuit claiming the company encouraged doctors to prescribe an anti-psychotic drug to children, veterans and the elderly outside its intended use. Seroquel is approved by the U.S. Food...

The FDA is considering halting a safety study on GlaxoSmithKline's diabetes drug Avandia, The Wall Street Journal reported Sunday. Previous studies have linked Avandia to an increased risk of heart attacks. The implication is a serious threat to the continued sale of Avandia in the U.S.

While it may be only one insurer -- UnitedHealth Group -- focusing on only one disease -- Type 2 diabetes -- the new program announced by UnitedHealth and the YMCA may be a sign of things to come. Clearly, UnitedHealth understands that spending on disease prevention now can save billions later....

PepsiCo will stop selling its full-sugar drinks in primary and secondary schools around the world by 2012.

Federal regulators approved Novo Nordisk's new once-daily injection for treating Type 2 diabetes Victoza, driving shares higher. Shares of Amylin Pharmaceuticals also rallied as the approval of Victoza raises hopes that Amylin's rival drug will also get the greenlight.